Safety and Tolerability of Abelacimab (MAA868) vs. Rivaroxaban in Patients With Atrial Fibrillation
Status:
Recruiting
Trial end date:
2023-05-01
Target enrollment:
Participant gender:
Summary
The purpose of the ANT-006 study is to evaluate the bleeding profile of abelacimab relative
to rivaroxaban in patients with atrial fibrillation (AF) at moderate-to-high risk of stroke.